EU Health Commissioner Dalli’s Resignation Leaves Unfinished Business For Pharma
This article was originally published in The Pink Sheet Daily
Executive Summary
John Dalli has resigned following allegations of fraud, bringing to an end a successful, but controversial career, and leaving the future of a number of legislative programs he championed – including anti-counterfeiting, risk assessments and biosimilar reviews – up in the air.